The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08

Related events

• Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sep 14
• Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.Sep 17
• Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.Aug 1
• GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.Sep 14
• Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Wed 22:45